Person:
ÖZYİĞİT, MUSA ÖZGÜR

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÖZYİĞİT

First Name

MUSA ÖZGÜR

Name

Filters

20202
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Her-2 positivity rate in dogs with mammary carcinoma: A systematic review and meta-analysis
    (Hellenic Veterinary Medical Soc, 2020-04-01) Uzabacı, Ender; UZABACI, ENDER; Özyiğit, Musa Özgür; ÖZYİĞİT, MUSA ÖZGÜR; Ercan, İlker; Arda, O.; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/ Patoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/ Biyoistatistik Anabilim Dalı.; 0000-0002-9634-0055; 0000-0002-2382-290X; JPL-5273-2023; ABF-2367-2020; AAR-6478-2021
    Human epidermal growth factor receptor 2 (HER-2) plays an essential role in cell growth and survival. HER-2 overexpression occurs in 20-30% of human breast tumors and has prognostic value as it is associated with disease progression. HER-2 overexpression is also associated with tumor progression and metastasis in malignant mammary tumors of the canine. However, in the literature, different positivity classifications/scoring were used in the evaluation of HER-2 status, and there is no consensus in terms of scoring of HER-2 expression in canine mammary tumors. In this study, it was aimed to estimate the HER-2 positivity rate by evaluating the results of the study using different positivity classifications by meta-analysis. In this context, by using "HER-2 canine mammary tumor" keywords, Pubmed and Web of Science electronic databases were scanned until February 2019, and a total of 97 related studies were found. However, 20 of these studies were used for the analysis. Two different meta-analyses were performed to evaluate the HER-2 positivity status with "2+ and 3+" and "3+" scores. As a result, HER-2 positivity rates were determined at 25.87% and 25.99% for the studies using "2+/3+" scores and "3+" respectively for HER-2 positivity. Therefore, this result suggests that the rate of HER-2 positivity is similar between humans and dogs.
  • No Thumbnail Available
    Publication
    Efficacy and toxicity of doxorubicin and cyclophosphamide for the neoadjuvant treatment of locally advanced stage canine mammary tumors
    (Kafkas Univ, Veteriner Fakultesi Dergisi, 2020-11-01) Shahzad, Abid Hussain; Kuruoglu, Fikriye Ecem; Özyiğit, Musa Özgür; ÖZYİĞİT, MUSA ÖZGÜR; Nak, Deniz; NAK, DENİZ; Küpeli, Zehra Avcı; Ekici, Zeynep Merve; Koca, Davut; KOCA, DAVUT; Avcılar, Talha; Nak, Yavuz; NAK, YAVUZ; Sahin, Mustafa Eren; ; Bursa Uludağ Üniversitesi/Veteriner Fakültesi/Doğum ve Jinekoloji Anabilim Dalı.; 0000-0002-6715-8529; 0000-0003-1853-4679; 0000-0002-7962-6959; 0000-0001-7034-9644; 0000-0002-8623-8292; AAH-5494-2021; AAH-2873-2021; AAI-6709-2021; AAR-6478-2021
    The aim of this study was to investigate the effect and toxicity of a doxorubicin cyclophosphamide combination for neoadjuvant use in dogs with locally advanced mammary tumors. A total of 16 dogs with locally advanced mammary tumors aged 8-14 years was used in this study. Samples were taken from all the dogs via Tru-Cut biopsy and fine needle aspiration biopsy of the lymph nodes prior to neoadjuvant chemotherapy. The samples were sent to the pathology laboratory for histopathological examination. Based on the histopathology results, mammary tumors were diagnosed as adenocarcinoma (n=13), tubulopapillary carcinoma (n=2) and malignant mixed tumors (n=1). For the neoadjuvant chemotherapy, doxorubicin (25-30 mg/m(2)) and cyclophosphamide (100 mg/m(2)) were administered via slow IV injection 4 times at 3-week intervals. Clinical findings such as fever, vomiting, anorexia, lethargy, weight loss, alopecia, enteritis, hematuria, and skin ulceration and laboratory findings such as a decrease in neutropenia and hematocrit values were observed. Based on the longest diameter of the tumors before and after four weeks of chemotherapy, a complete response was detected in 2 dogs (12.5%), a partial response was observed in 9 dogs (56.25%) and the disease was stable in 5 dogs (31.25%). According to results, the toxicity, and efficacy of a doxorubicin and cyclophosphamide combination for neoadjuvant chemotherapy in dogs with locally advanced mammary tumors is acceptable, and the treatment is promising.